Under kliniske forsøg med intravenøst busulfan lå 90% af patienternes AUC under den øvre AUC - grænse (1. 500 μmol/ min), og mindst 80% lå inden for det tilsigtede terapeutiske vindue (9001500 μMol. min).
During clinical trials with intravenous busulfan, 90% of patients AUCs were below the upper AUC limit (1500 µMol. minute) and at least 80% were within the targeted therapeutic window (900- 1500 µMol. minute).